Report #2830579

Overview

Sex

Unknown

Age

Age unknown

State

TX

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Priorix was administered intramuscularly instead of subcutaneously.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix was administered intramuscularly instead of subcutaneously.). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:06-MAR-2025 Pharmacist reports Priorix was administered intramuscularly instead of subcutaneously, which led to subcutaneous injection formulation administered by other route The reporter consented to follow up. No details at time of call were available.